Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)

Rolando Cimaz, P. L. Meroni, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review

Abstract

The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies (aPL), demonstrated by ELISAs for antibodies against phospholipids and associated phospholipid-binding cofactor proteins and/or a circulating lupus anticoagulant (LA) together with diverse systemic clinical manifestations such as thrombosis, and recurrent spontaneous abortions. According to the criteria set out in Sydney the only neurological manifestations that can be suitable as APS classification criteria are ischemic events (stroke and transient ischemic attacks). However, other neurological manifestations, including seizures in particular, have been repeatedly reported in APS patients. The present review will summarize recent research on the association of aPL, as well as other autoantibodies, with seizure disorders, with or without concomitant SLE.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalLupus
Volume15
Issue number4
DOIs
Publication statusPublished - 2006

Keywords

  • Antiphospholipid
  • Autoantibodies
  • Autoimmune
  • Epilepsy
  • Seizures
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)'. Together they form a unique fingerprint.

Cite this